title: Limb-preserving treatment for soft tissue sarcomas of the extremities. The significance of surgical margins.
abstract: METHODS
  Between 1970 and 1990, 74 patients with extremity soft tissue sarcomas began a regimen of limb-sparing surgery and irradiation. Ninety-two percent received postoperative irradiation, 7% received preoperative irradiation, and one patient was treated with radiation after an incisional biopsy only. Radiation was administered with a shrinking-field technique (median total dose, 63 Gy; range, 39.6-71 Gy), with 14 patients receiving interstitial brachytherapy as a component of treatment. Ten patients received adjuvant chemotherapy.
  
  
  RESULTS
  Local control of disease was 82% at 5 years, and 95% after salvage therapy. The actuarial risk of distant disease recurrence was 27%, with an overall survival rate of 70% at 5 years. Histologic subtype, tumor grade, size of tumor, location of tumor, status of the surgical margins, use of chemotherapy, radiation dose, interval until initiation of radiation therapy, and use of a brachytherapy boost were analyzed to determine their effect on survival, local control, and freedom from distant metastasis. Microscopic involvement of the surgical margins predicted for local disease recurrence (P = 0.0002), distant disease recurrence (P = 0.008), and poorer overall survival (P = 0.02). Low histologic grade was favorably correlated with freedom from distant disease recurrence (P = 0.004) and survival (P = 0.002). Patients with liposarcomas had superior local control (P = 0.004) compared with patients with tumors of other histologic subtypes. Five patients experienced a complication of therapy, for an actuarial risk of 10% at 5 years. Only two patients required hospital admittance for treatment-related morbidity.
  
  
  CONCLUSIONS
  These findings support the continued use of limb-preserving management for extremity sarcomas and emphasize the importance of the status of the surgical margins.
authors.affiliation: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
authors.forename: S H
authors.initials: SH
authors.lastname: Herbert
authors.forename: B W
authors.initials: BW
authors.lastname: Corn
authors.forename: L J
authors.initials: LJ
authors.lastname: Solin
authors.forename: R M
authors.initials: RM
authors.lastname: Lanciano
authors.forename: D J
authors.initials: DJ
authors.lastname: Schultz
authors.forename: W G
authors.initials: WG
authors.lastname: McKenna
authors.forename: L R
authors.initials: LR
authors.lastname: Coia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D003131:Combined Modality Therapy; D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy / Q000601:surgery; D011379:Prognosis; D011879:Radiotherapy Dosage; D016879:Salvage Therapy; D012509:Sarcoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery*; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*